DNA methylation array analyses identified breast cancer-associated HYAL2 methylation in peripheral blood

International Journal of Cancer

Volumn 136, Issue 8, 2015, Pages 1845-1855

  Yang, Rongxi ^a,b   Pfütze, Katrin ^a,b   Zucknick, Manuela ^b   Sutter, Christian ^a   Wappenschmidt, Barbara ^c   Marme, Frederik ^a   Qu, Bin ^d   Cuk, Katarina ^a,b   Engel, Christoph ^e   Schott, Sarah ^a   Schneeweiss, Andreas ^a   Brenner, Hermann ^b   Claus, Rainer ^b   Plass, Christoph ^b   Bugert, Peter ^a   Hoth, Markus ^d   Sohn, Christof ^a   Schmutzler, Rita ^c   Bartram, Claus R ^a   Burwinkel, Barbara ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Breast cancer; Early detection; HYAL2; Marker; Methylation

Indexed keywords

DNA; CELL ADHESION MOLECULE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HYAL2 PROTEIN, HUMAN; HYALURONOGLUCOSAMINIDASE; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; CONTROLLED STUDY; CPG ISLAND; DISEASE ACTIVITY; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE REPLICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYALURONOGLUCOSAMINIDASE 2 GENE; MALE; MOLECULAR PATHOLOGY; ONCOGENE; OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; SYNDROME DELINEATION; T LYMPHOCYTE; ADULT; AGED; BLOOD; BREAST NEOPLASMS; DNA MICROARRAY; EARLY DIAGNOSIS; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; CPG ISLANDS; DNA METHYLATION; EARLY DETECTION OF CANCER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GPI-LINKED PROTEINS; HUMANS; HYALURONOGLUCOSAMINIDASE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84922575269     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29205     Document Type: Article

References (50)

1. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001;2:133-40.
2. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan. iarc.fr.
3. Warner E. Clinical practice. Breast-cancer screening. N Engl J Med 2011;365:1025-32.
4. Benson JR, Jatoi I, Keisch M, et al. Early breast cancer. Lancet 2009;373:1463-79.
5. Punglia RS, Morrow M, Winer EP, et al. Local therapy and survival in breast cancer. N Engl J Med 2007;356:2399-405.
6. Wacholder S, Hartge P, Prentice R, et al. Performance of common genetic variants in breastcancer risk models. N Engl J Med 2010;362:986-93.
7. Decarli A, Calza S, Masala G, et al. Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition cohort. J Natl Cancer Inst 2006;98:1686-93.
8. Pharoah PD, Antoniou A, Bobrow M, et al. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002;31:33-6.
9. Weber M, Davies JJ, Wittig D, et al. Chromosomewide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005;37:853-62.
10. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143-53.
11. Breitling LP, Yang R, Korn B, et al. Tobaccosmokingrelated differential DNA methylation: 27K discovery and replication. Am J Hum Genet 2011;88:450-7.
12. Heyn H, Carmona FJ, Gomez A, et al. DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker. Carcinogenesis 2013;34:102-8.
13. Langevin SM, Koestler DC, Christensen BC, et al. Peripheral blood DNA methylation profiles are indicative of head and neck squamous cell carcinoma: an epigenome-wide association study. Epigenetics 2012;7:291-9.
14. Marsit CJ, Koestler DC, Christensen BC, et al. DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer. J Clin Oncol 2011;29:1133-9.
15. Teschendorff AE, Menon U, Gentry-Maharaj A, et al. An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One 2009;4:e8274.
16. Brennan K, Garcia-Closas M, Orr N, et al. Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res 2012;72:2304-13.
17. Flanagan JM, Munoz-Alegre M, Henderson S, et al. Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. Hum Mol Genet 2009;18:1332-42.
18. Iwamoto T, Yamamoto N, Taguchi T, et al. BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation. Breast Cancer Res Treat 2011;129:69-77.
19. Widschwendter M, Apostolidou S, Raum E, et al. Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One 2008;3:e2656.
20. Xu Z, Bolick SC, DeRoo LA, et al. Epigenomewide association study of breast cancer using prospectively collected sister study samples. J Natl Cancer Inst 2013;105:694-700.
21. Meindl A. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 2002;97:472-80.
22. Yang R, Schlehe B, Hemminki K, et al. A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk. Breast Cancer Res Treat 2010;121:693-702.
23. Hayes DF, Allred C, Anderson BO, et al. Breast cancer. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC cancer staging manual, 7th edn. New York: Springer, 2010. 345-76.
24. Alan HL, Andrew RC, Davor B, et al. A method for ameliorating autoimmune disease by passive transfer of IVIg-primed leukocytes. Nat Protoc 2006. http://www.nature.com/protocolexchange/protocols/44#/main.
25. Steemers FJ, Chang W, Lee G, et al. Wholegenome genotyping with the single-base extension assay. Nat Methods 2006;3:31-3.
26. Breitling LP, Salzmann K, Rothenbacher D, et al. Smoking, F2RL3 methylation, and prognosis in stable coronary heart disease. Eur Heart J 2012;33:2841-8.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) method. Methods 2001;25:402-8.
28. Simas AB, Barreto-Souza W, Rocha AV. Improved estimators for a general class of beta regression models. Comput Stat Data Anal 2010;54:348-66.
29. Houseman EA, Accomando WP, Koestler DC, et al. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics 2012;13:86.
30. Reinius LE, Acevedo N, Joerink M, et al. Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. PLoS One 2012;7:e41361.
31. Moore LE, Pfeiffer RM, Poscablo C, et al. Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol 2008;9:359-66.
32. Xu X, Gammon MD, Hernandez-Vargas H, et al. DNA methylation in peripheral blood measured by LUMA is associated with breast cancer in a population-based study. FASEB J 2012;26:2657-66.
33. Wu HC, John EM, Ferris JS, et al. Global DNA methylation levels in girls with and without a family history of breast cancer. Epigenetics 2011;6:29-33.
34. Choi JY, James SR, Link PA, et al. Association between global DNA hypomethylation in leukocytes and risk of breast cancer. Carcinogenesis 2009;30:1889-97.
35. Afratis N, Gialeli C, Nikitovic D, et al. Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J 2012;279:1177-97.
36. Duterme C, Mertens-Strijthagen J, Tammi M, et al. Two novel functions of hyaluronidase-2 (Hyal2) are formation of the glycocalyx and control of CD44-ERM interactions. J Biol Chem 2009;284:33495-508.
37. Hesson LB, Cooper WN, Latif F. Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene 2007;26:7283-301.
38. Saito T, Kawana H, Azuma K, et al. Fragmented hyaluronan is an autocrine chemokinetic motility factor supported by the HAS2-HYAL2/CD44 system on the plasma membrane. Int J Oncol 2011;39:1311-20.
39. Wang F, Grigorieva EV, Li J, et al. HYAL1 and HYAL2 inhibit tumour growth in vivo but not in vitro. PLoS One 2008;3:e3031.
40. Teschendorff AE, Menon U, Gentry-Maharaj A, et al. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res 2010;20:440-6.
41. Christensen BC, Houseman EA, Marsit CJ, et al. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet 2009;5:e1000602.
42. Bast RC, Jr, Ravdin P, Hayes DF, et al.; American Society of Clinical Oncology Tumor Markers Expert P. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78.
43. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-56.
44. Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003;138:168-75.
45. Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 2012;307:1394-404.
46. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005;23:8469-76.
47. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005;365:1769-78.
48. Pisano ED, Gatsonis C, Hendrick E, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 2005;353:1773-83.
49. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75-89.
50. Miller AB, Wall C, Baines CJ, et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 2014;348:g366.